Transaction DateRecipientSharesTypePriceValue
9th October 2020James Arthur Bristol19,370Open or private sale$53.35$1,033,451.48
9th October 2020James Arthur Bristol23,541Exercise of derivative$1.89$44,492.49
9th October 2020James Arthur Bristol200Open or private sale$55.43$11,086.00
9th October 2020James Arthur Bristol3,971Open or private sale$54.53$216,531.09
2nd October 2020Matthew L Sherman2,632Payment by withholding$51.15$134,618.11
1st October 2020Michael Douglas Taylor20,365Exercise of derivative$1.89$38,489.85
1st October 2020Michael Douglas Taylor23,886Open or private sale$51.98$1,241,596.67
1st October 2020Michael Douglas Taylor101,114Open or private sale$51.52$5,208,887.71
1st October 2020Michael Douglas Taylor104,635Exercise of derivative$1.89$197,760.15
14th September 2020Thomas Patrick Kelly3,000Exercise of derivative$1.89$5,670.00
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Deciphera Pharmaceuticals, Inc. develops and manufactures kinase inhibitor treatments for cancer. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.


Ticker: DCPH
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1654151
Employees: 258
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $155 M (29%)
Inventory, Net: $1 M (0%)
Assets, Current: $633 M (6%)
Property, Plant and Equipment, Net: $10 M (51%)
Assets: $686 M (10%)
Accounts Payable, Current: $13 M (-35%)
Liabilities, Current: $51 M (-14%)
Liabilities: $67 M (-12%)
Common Stock, Value, Issued: $561 Th (8%)
Common Stock, Shares, Issued: $56 M (8%)
Additional Paid in Capital, Common Stock: $1 B (20%)
Retained Earnings (Accumulated Deficit): $628 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $8 Th (-92%)
Stockholders' Equity (Parent): $620 M (0%)
Liabilities and Equity: $686 M (10%)
Revenue: $7 M (0%)
Cost of Revenue: $8 Th (0%)
Research and Development: $46 M (-52%)
Operating Income/Loss: $69 M (-52%)
Other Income, net: $2 M (-59%)